Werbung
Hier die News dazu:
Shares of EyeGate Pharmaceuticals Inc. EYEG, +47.39% rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better than the standard of care, which is a bandage contact lens, in patients in need of corneal wound repair. EyeGate plans to submit a de novo application to the Food and Drug Administration in the first six months of 2020. "If approved, [it] will be the first product indicated to repair corneal defects, as well as the first prescription hyaluronic acid eye drop in the U.S.," EyeGate CEO Stephen From said in a release. The company said it expects to receive additional data next week. EyeGate stock has fallen 31% year-to-date. The S&P 500 SPX, +0.01% has jumped 24%.
www.marketwatch.com/story/...-2019-11-22?mod=newsviewer_click
old.nasdaq.com/de/symbol/eyeg/real-time
About
www.eyegatepharma.com/
Shares of EyeGate Pharmaceuticals Inc. EYEG, +47.39% rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better than the standard of care, which is a bandage contact lens, in patients in need of corneal wound repair. EyeGate plans to submit a de novo application to the Food and Drug Administration in the first six months of 2020. "If approved, [it] will be the first product indicated to repair corneal defects, as well as the first prescription hyaluronic acid eye drop in the U.S.," EyeGate CEO Stephen From said in a release. The company said it expects to receive additional data next week. EyeGate stock has fallen 31% year-to-date. The S&P 500 SPX, +0.01% has jumped 24%.
www.marketwatch.com/story/...-2019-11-22?mod=newsviewer_click
old.nasdaq.com/de/symbol/eyeg/real-time
About
www.eyegatepharma.com/
